Abstract
-
IBRO Neurosci Rep. 2022 Dec 12;14:28-37. doi: 10.1016/j.ibneur.2022.12.002. eCollection 2023 Jun.
The role of DNA methylation in progression of neurological disorders and neurodegenerative diseases as well as the prospect of using DNA methylation inhibitors as therapeutic agents for such disorders.
Rasmi Y(1)(2), Shokati A(3)(4)(5), Hassan A(6)(7), Aziz SG(1)(2), Bastani S(8), Jalali L(2), Moradi F(9), Alipour S(1)(2)(10).
Author information: (1)Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran. (2)Department of Biochemistry, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran. (3)Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. (4)Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences (TUMS), Tehran, Iran. (5)Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. (6)Dipartimento di Oncologia ed Emato-Oncologia, Università Degli Studi Di Milano, Via Festa del Perdono, Milano, Italy. (7)Laboratory of Translatonal Neurosciences, European School of Molecular Medicine, CEINGE Biotecnologie Avanzate S.c.a.rl.Via Gaetano Salvatore, Naples, Italy. (8)Stem cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran. (9)Tissue Engineering and Applied Cell Sciences Division, Department of Anatomical Sciences, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. (10)Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.
Genome-wide studies related to neurological disorders and neurodegenerative diseases have pointed to the role of epigenetic changes such as DNA methylation, histone modification, and noncoding RNAs. DNA methylation machinery controls